THU0148 Increase of night qt-interval duration in rheumatoid arthritis patients treated with tofacitinib during 12-month follow-up

Objectives to evaluate dynamic of ECG parameters in RA pts treated with tofacitinib (TOFA) during 12-month follow-up. Methods After 12-m follow-up the ECG parameters by 12 lead ECG and 24h ECG was assessed in 28 RA pts treated with TOFA (22 women, median age 54 [40;62] years, disease duration 39,5 [16,5;60,0] m, moderate to high activity (DAS28–5.1 [4.6;6.0], SDAI–26 (21;34)), positive for ACCP (75%)/RF (79%), who were non-responders to MTX at least 15 mg/week and/or other synthetic DMARDs and bDMARDs. TOFA therapy was started in all pts with dose 5 mg BID per os followed by the dose escalation to 10 mg BID in 8 (29%) pts. TOFA used in combination with MTX in 27 (96%) pts, leflunomide in 1 (4%). Low-dose oral corticosteroids ( 21%, subclinical carotid atherosclerosis-64%, cardiac heart failure with preserved ejection fraction-7%. Cardioprotective therapy received 16 (57%) pts (beta-blockers–7, angiotensin II receptor type 2/ACE inhibitors–11, statins–11, dihydropyridine calcium channel blockers-7). Results There was no difference in heart rate (HR), QTc interval duration, QRS duration measured by 12-lead ECG in RA pts treated with TOFA (table 1). However, an increase in PQ interval duration was observed (p=0,04). There were significantly decrease of mean HR (p 0.05). A change in QTc duration correlated negatively with dynamics of DAS 28, SDAI (r=-0,4, p Conclusions A significant decrease in HR and an increase in QRS, night QTc interval duration, number of ventricular premature beats by 24h ECG were observed in RA pts treated with tofacitinib (TOFA) during 12-month follow-up. QTc duration correlated with dynamic of disease activity, DM type 2 and diastolic BP. Disclosure of Interest None declared